Replimune Group (NASDAQ:REPL) CFO Emily Luisa Hill Sells 9,256 Shares of Stock

Replimune Group, Inc. (NASDAQ:REPL) CFO Emily Luisa Hill sold 9,256 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $14.28, for a total value of $132,175.68. Following the sale, the chief financial officer owned 215,852 shares in the company, valued at approximately $3,082,366.56. This trade represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Emily Luisa Hill also recently made the following trade(s):

• On Monday, August 10th, Emily Luisa Hill sold 11,448 shares of Replimune Group stock. The shares were sold at an average price of $12.97, for a total value of $148,480.56.

Replimune Group Trading Down 4.9%

Shares of NASDAQ REPL opened at $14.81 on Thursday. Replimune Group, Inc. has a 1-year low of $1.50 and a 1-year high of $15.70. The company has a market cap of $1.39 billion, a PE ratio of -4.70 and a beta of 0.88. The company has a current ratio of 5.23, a quick ratio of 4.79 and a debt-to-equity ratio of 1.00. The company has a 50-day moving average of $11.02 and a two-hundred day moving average of $7.95.

Replimune Group (NASDAQ:REPL) last released its earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). As a group, equities analysts expect that Replimune Group, Inc. will post -2.78 earnings per share for the current fiscal year.

Key Headlines Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Replimune announced inducement equity awards for Chief Commercial Officer Michelle DiNapoli under Nasdaq Listing Rule 5635(c)(4). The grants are intended to support employee recruitment and retention, but will modestly increase potential share dilution. Replimune Announces Inducement Grants
• Neutral Sentiment: CFO Emily Luisa Hill sold 9,256 shares for approximately $132,176 at an average price of $14.28. The filing states the sale was made to cover tax-withholding obligations tied to vested equity awards; she continues to own 215,852 shares, reducing the signal of discretionary insider selling. SEC Insider Transaction Filing
• Negative Sentiment: Several law firms publicized the securities class action and reminded investors of the October 5, 2026 deadline to seek lead-plaintiff status. The complaints allege Replimune’s filings did not adequately disclose that FDA concerns about the RP1 study design remained unresolved. Although the allegations have not been proven, the legal uncertainty creates an overhang and could increase potential costs or liabilities. Replimune Securities Fraud Lawsuit Deadline Alert

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of REPL. BlackRock Inc. acquired a new position in shares of Replimune Group in the second quarter worth approximately $99,171,000. Balyasny Asset Management L.P. increased its position in Replimune Group by 507.4% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after purchasing an additional 2,195,448 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in Replimune Group during the 4th quarter valued at approximately $17,568,000. Commodore Capital LP acquired a new stake in Replimune Group during the 4th quarter valued at approximately $13,851,000. Finally, EcoR1 Capital LLC bought a new position in Replimune Group during the 1st quarter worth approximately $7,650,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on REPL. Weiss Ratings cut Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Replimune Group in a research note on Wednesday, August 12th. BMO Capital Markets raised Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price target for the company in a research report on Tuesday, June 30th. Finally, Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Replimune Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.86.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.